MDL-1 USES
The invention provides methods for treating bone resorption disorders with antagonists of MDL-1.
1 . A method of modulating bone resorption in a subject comprising administering to the subject an effective amount of an antibody or antibody fragment thereof that specifically binds MDL-1 (SEQ ID NO: 2 or 4).
2 . The method of claim 1 , wherein the antibody is humanized.
3 . The method of claim 1 , wherein the antibody is fully human,
4 . The method of claim 1 , wherein the antibody is chimeric.
5 . The method of claim 1 , wherein the antibody fragment is a Fab, Fab2, or Fv antibody fragment.
6 . The method of claim 1 , wherein the antibody or antibody fragment is conjugated to another chemical moiety.
7 . The method of claim 6 , wherein the chemical moiety is polyethylene glycol (PEG).
8 . The method of claim 1 , wherein the antibody inhibits bone resorption.
9 . The method of claim 8 , wherein bone resorption is caused by inflammation.
10 . The method of claim 1 , wherein the antibody or antibody fragment inhibits osteoclast formation or activation.
11 . A method of modulating bone resorption in a subject comprising administering to the subject an effective amount of a soluble MDL-1 protein (SEQ ID NO: 2 or 4).
12 . The method of claim 11 , wherein the soluble MDL-1 protein is conjugated to a chemical moiety.
13 . The method of claim 12 , wherein the chemical moiety is PEG.
14 . The method of claim 11 , wherein the soluble MDL-1 protein is fused to a heterologous protein.
15 . The method of claim 14 , wherein the heterologous protein comprises an Fc portion of an antibody molecule.
16 . The method of claim 10 , wherein the soluble MDL-1 protein inhibits bone resorption.
17 . The method of claim 15 , wherein bone resorption is caused by inflammation.
18 . The method of claim 11 , wherein the soluble MDL-1 protein inhibits osteoclast formation or activation.